A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
This research is looking at teclistamab, a new medicine, when given alongside existing anti-cancer drugs for people with multiple myeloma. The main goal is to understand how safe these combinations are and how well they are tolerated by patients. Researchers also want to find the best possible doses for these new treatment mixtures. This is a very early-stage study (Phase 1), meaning it's primarily focused on safety. It aims to see if these combinations could be a good way to treat multiple myeloma, potentially offering new options for patients who may not have responded well to previous treatments.
At a glance
What is this study about?
This study is about a type of blood cancer called multiple myeloma. Our bodies have different types of cells, and plasma cells are a special type that helps fight off infections. In multiple myeloma, these plasma cells grow too much and crowd out healthy cells in the bone marrow, where blood cells are made. This can lead to various health problems.
Researchers are looking into a new medicine called teclistamab. They want to see how well it works and how safe it is when given with other established cancer treatments. Think of it like trying out a new ingredient in a recipe alongside ingredients you already know – you want to make sure the new mix is safe and tastes good! The aim is to find the best and safest way to use teclistamab with other drugs, hoping to improve treatment for multiple myeloma.
This is an early phase study, which means it's mainly focused on safety and finding the right doses. If these combinations are found to be safe and show promise, they could be studied further in larger groups of patients. Ultimately, the hope is to develop more effective treatments that can help people with multiple myeloma live healthier lives.
Key takeaways
- This study is for people with multiple myeloma.
- It's testing a new drug, teclistamab, in combination with other treatments.
- The main goals are to check safety and find the best doses.
- It's an early-stage (Phase 1) clinical trial.
- Participation involves regular clinic visits and specific assessments.
Who may be eligible?
To join this study, you must have been diagnosed with multiple myeloma. Depending on which specific treatment group you might be in, there are different requirements for how much previous treatment you've had.
For example, some groups are for people who have tried one to three other treatments, including specific types of drugs like a 'proteasome inhibitor' and 'lenalidomide'. Other groups might be for people who haven't had lenalidomide before, or who have already had three or more previous treatments, or even for those who have newly diagnosed multiple myeloma.
You also need to have clear signs of your multiple myeloma that can be measured, such as certain levels in your blood or urine. If you are a woman who could become pregnant, you'll need to have a negative pregnancy test before starting. The study is open to anyone aged 18 or older.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I have been diagnosed with multiple myeloma.
- I am at least 18 years old.
- My myeloma can be measured by doctors (e.g., in blood or urine tests).
- I fit one of the descriptions for previous treatments (e.g., 1-3 prior treatments, or newly diagnosed, etc.).
- If I am a woman who could get pregnant, I am willing to take a pregnancy test.
What does participation involve?
Taking part in this study would involve regular visits to the clinic for assessments. These assessments will include blood tests, urine tests, and other procedures to check how you are responding to the treatment and to monitor your health. You would receive teclistamab along with one or more other study drugs, as decided by the research team based on your specific treatment plan. The number of visits and the full length of your participation would depend on which treatment group you are in and how you respond to the medication. The research team will explain all the details of your specific schedule.
Potential risks and benefits
Locations (27)
- University of Alabama at BirminghamVerified postcodeBirmingham, United States
- University of California San FranciscoVerified postcodeSan Francisco, United States
- Colorado Blood Cancer InstituteVerified postcodeDenver, United States
- Winship Cancer Institute Emory UniversityVerified postcodeAtlanta, United States
- Indiana University Melvin and Bren Simon Cancer CenterVerified postcodeIndianapolis, United States
- Washington University School Of MedicineVerified postcodeSt Louis, United States
- Hackensack University Medical CenterVerified postcodeHackensack, United States
- Memorial Sloan-Kettering Cancer CenterVerified postcodeNew York, United States
- Weill Cornell Medical CollegeVerified postcodeNew York, United States
- Levine Cancer InstituteVerified postcodeCharlotte, United States
- University of Pittsburgh Medical CenterVerified postcodePittsburgh, United States
- Tennessee OncologyVerified postcodeNashville, United States
Common questions
What is multiple myeloma?
Multiple myeloma is a type of cancer that affects plasma cells, a type of white blood cell found in the bone marrow.
What is 'Phase 1' of a clinical trial?
Phase 1 is the earliest stage of a trial where researchers mainly focus on checking the safety of a new medicine or combination, and finding the right dose.
What is teclistamab?
Teclistamab is an experimental medicine being tested in this study for treating multiple myeloma.
Will I know which treatment I get?
Yes, in this type of study, you and your doctor will know exactly which combination of medicines you are receiving.
How long will the study last?
The exact length of your participation will depend on the specific treatment group and your response, but the research team will explain this to you.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.